| Description | Ellipticine (Elliptisine) is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 0.67±0.06, 1.25±0.13, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.49±0.04, 0.44±0.03, and 1.48±0.62 μM for Leukemia HL-60, Breast adenocarcinoma MCF-7, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-4, Neuroblastoma UKF-NB-3, and Glioblastoma U87 mg cell, respectively. |
| Target activity | IMR-32 cells:0.27±0.02μM, MCF-7 cells:1.25±0.13μM, UKF-NB-3 cells:0.44±0.03μM , HL-60 cells (leukemia):0.67±0.06μM, UKF-NB-4 cells:0.49±0.04μM, U-87 MG cells (Glioblastoma):1.48±0.62 μM |
| Synonyms | 玫瑰树碱, NSC 71795, Elliptisine |
| molecular weight | 246.31 |
| Molecular formula | C17H14N2 |
| CAS | 519-23-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 5 mg/mL (20.3 mM) |
| References | 1. Savorani C, et al. Leuk Lymphoma. 2015 Mar;56(3):739-47. |